NASDAQ: PREPrenetics Global Ltd Stock
$4.06-0.24 (-5.58%)
Updated Mar 21, 2025
PRE Price
$4.06
Fair Value Price
N/A
Market Cap
$49.62M
52 Week Low
$2.85
52 Week High
$7.84
P/E
-1.02x
P/B
0.28x
P/S
1.94x
PEG
N/A
Dividend Yield
N/A
Revenue
$25.56M
Earnings
-$49.01M
Gross Margin
55.4%
Operating Margin
-193.45%
Profit Margin
-191.7%
Debt to Equity
0.31
Operating Cash Flow
N/A
Beta
0.48
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PRE Overview
Prenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; Circle Medical, a diagnostic testing product; and Circle One and F1x/Fem. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PRE's potential to beat the market
- PRE doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
B
PRE
RankedUnranked of 45
RankedUnranked of 45
Be the first to know about important PRE news, forecast changes, insider trades & much more!
PRE News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PRE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PRE is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PRE is good value based on its book value relative to its share price (0.28x), compared to the US Diagnostics & Research industry average (3.77x)
P/B vs Industry Valuation
PRE is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PRE due diligence checks available for Premium users.
Valuation
PRE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.02x
Industry
44.48x
Market
31.55x
PRE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.28x
Industry
3.77x
PRE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PRE's financial health
Profit margin
Revenue
$7.8M
Net Income
-$10.7M
Profit Margin
-137.2%
PRE's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$235.8M
Liabilities
$55.7M
Debt to equity
0.31
PRE's short-term assets ($69.12M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PRE's short-term assets ($69.12M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PRE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
PRE vs Diagnostic & Research Stocks
Prenetics Global Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.